{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:04:30Z","timestamp":1789657470441,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100016318","name":"Cerus Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010481","name":"Etablissement Fran\u00e7ais du Sang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto\u2010immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion\u2010transmitted infection (TTI). Amotosalen\u2010UVA Pathogen Reduction technology is FDA approved to manufacture pathogen\u2010reduced plasma, cryoprecipitate reduced (PRPCR), a form of cryoprecipitate poor plasma (CPP) with potentially improved TPE outcomes and reduced TTI risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PRPCR was manufactured from pathogen\u2010reduced (PR) plasma. Thrombin generation, fibrinogen, Factors II, V, VII, VIII, IX, X, XI, XIII, VWF, ADAMTS13, Protein C, Protein S, \u03b1\u20102 plasmin inhibitor (\u03b1\u20102 PI), IgG, IgM, and IgA were measured. Microfluidic chamber assays at variable shear rates characterized PRPCR\u2010mediated platelet adhesion and aggregation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to PR plasma, fibrinogen, Factor VIII, and VWF levels were depleted in PRPCR. Factors II, V, VII, IX, X, XI, XIII, thrombin generation, Protein C, Protein S, \u03b1\u20102 PI, ADAMTS13, and immunoglobulins were conserved. At low wall shear rates (300\u2009s\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) PRPCR supported platelet adhesion. Perfusion of plasma\u2010free blood containing PRPCR flowed over immobilized VWF binding peptide (100\u2009\u03bcg\/mL) and showed absence of platelet adhesion. Perfusion of plasma\u2010free blood containing PRPCR flowed over immobilized collagen (200\u2009\u03bcg\/mL) at high wall shear rate (1500\u2009s\n                      <jats:sup>\u22121<\/jats:sup>\n                      ) and demonstrated no platelet thrombus formation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRPCR retained hemostatic capacity, anti\u2010thrombotic proteins, and ADAMTS13, but collagen induced platelet aggregation was negligible at high shear due to depletion of functional high molecular weight VWF. PRPCR is a CPP option for TPE with reduced platelet\u2010mediated thrombotic risk and TTI risk, but with retention of plasma hemostatic capacity and immunoglobulins.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.70099","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:50:45Z","timestamp":1769853045000},"page":"664-676","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathogen\u2010reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4025-0874","authenticated-orcid":false,"given":"Florian","family":"Tupin","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, \u00c9tablissement Fran\u00e7ais du Sang (EFS) Grand Est, BPPS UMR_S 1255, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS)  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-7818","authenticated-orcid":false,"given":"Clarisse","family":"Mouriaux","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, \u00c9tablissement Fran\u00e7ais du Sang (EFS) Grand Est, BPPS UMR_S 1255, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS)  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-0175","authenticated-orcid":false,"given":"Beatrice","family":"Hechler","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, \u00c9tablissement Fran\u00e7ais du Sang (EFS) Grand Est, BPPS UMR_S 1255, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS)  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaja","family":"Kaastrup","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subra","family":"Yegneswaran","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Corash","sequence":"additional","affiliation":[{"name":"Cerus Corporation  Concord California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre H.","family":"Mangin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, \u00c9tablissement Fran\u00e7ais du Sang (EFS) Grand Est, BPPS UMR_S 1255, F\u00e9d\u00e9ration de M\u00e9decine Translationnelle de Strasbourg (FMTS)  Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-271445"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-243790"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000058401.34021.D4"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0193"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12371"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.04.007"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012376"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120826"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11070744"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1985.25686071422.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15807"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02991.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01238.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.01.004"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21996"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2006.05.014"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.10.007"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.1318.1318"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21302"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920100404"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05418.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21336"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00551.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04360.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12090"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250604"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188500"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13229"},{"key":"e_1_2_11_31_1","volume-title":"INTERCEPT\u00ae blood system for Cryoprecipitation package insert for the manufacturing of pathogen reduced plasma, cryoprecipitate reduced","author":"Cerus Corporation","year":"2024"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00867.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12697"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.70031"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-782-3:013"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235754"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011965"},{"key":"e_1_2_11_38_1","volume-title":"INTERCEPT\u00ae blood system for plasma","author":"Cerus Corporation","year":"2014"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-378935"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80983-6"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17083"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16819"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15739"},{"issue":"6","key":"e_1_2_11_44_1","first-page":"467","article-title":"Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity","volume":"19","author":"Cheng JH","year":"2021","journal-title":"Blood Transfus"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13670"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00216.x"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13100"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12663"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02579.x"},{"key":"e_1_2_11_50_1","volume-title":"Circular of Information for the use of human blood and blood components","author":"Association for the Advancement of Blood & Biotherapies (AABB), American Red Cross, America's Blood Centers (ABC), Armed Services Blood Program (ASBP)","year":"2024"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.70099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.70099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:17:20Z","timestamp":1789654640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.70099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/trf.70099"],"URL":"https:\/\/doi.org\/10.1111\/trf.70099","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"2025-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}